Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511363 | 0.90 | NLRP3 (0.61) | APPNLRP3HRH4SRC | |
| Trifluoroacetic Acid SCHEMBL4523507 | 0.89 | APP (0.53) | APPNLRP3HRH4SRCSLC2A1 | |
| SCHEMBL4526002 | 0.89 | HRH4 (0.49) | APPNLRP3HRH4SRCSLC2A1 | |
| SCHEMBL4531699 | 0.88 | APP (0.62) | APPNLRP3SLC2A1PDE5ATLR8 | |
| SCHEMBL4533460 | 0.83 | HRH4 (0.55) | APPNLRP3HRH4SRCPTPN1 | |
| SCHEMBL13888562 | 0.82 | HRH4 (0.47) | APPNLRP3HRH4SRCKCNH2 | |
| Trifluoroacetic Acid SCHEMBL4519252 | 0.80 | NLRP3 (0.51) | APPNLRP3HRH4SRCPTPN1 | |
| Trifluoroacetic Acid SCHEMBL4517024 | 0.79 | APP (0.54) | APPNLRP3SLC2A1PDE5ATLR7 | |
| SCHEMBL4534824 | 0.78 | APP (0.49) | APPNLRP3PTPN1 | |
| SCHEMBL4528798 | 0.78 | RAD52 (0.45) | APPNLRP3HRH4SLC2A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | APP 3531/4885NLRP3 618/4885HRH4 3834/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | APP 3531/4885NLRP3 618/4885HRH4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.